Heterozygous carriers of ATM pathogenic variants have been found to be at increased risk for breast, pancreatic, and prostate cancers and more recently there have been suggested associations with ovarian cancer and some reports of lymphoid malignancies [33]. This evidence concerns the gene ATM and prostate carcinoma.